Actin vs Spry
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
Actin
Best for affordable compounded semaglutide with B12 enhancementStarting at $133/mo
Spry
Best for Buyers seeking a multi-product wellness/longevity platform that combines compounded GLP-1s with anti-aging peptides under one membership, who are comfortable with nurse-practitioner intake review (vs MD) and willing to overlook the 'FDA Approved' badge framing on a compounded-medication platform.Starting at $199/mo
Side-by-Side Comparison
| Feature | Actin | Spry |
|---|---|---|
| Overall Score | ✓7.0/10 | 6.1/10 |
| Starting Price | ✓$133/mo | $199/mo |
| Editorial Rating | ✓3.5 ★ /5 | 3.1 ★ /5 |
| Features | 2 features | ✓10 features |
| States Available | 0 | 0 |
| Compounded | ✓ Yes | ✓ Yes |
| Brand Name | — | — |
| FSA/HSA Accepted | — | — |
| FDA Warnings | ✓None | 1 warning |
Pros & Cons
Actin
Pros
- ✓Semaglutide + B12 combination for added energy support
- ✓Transparent pricing — exact cost shown upfront with no hidden fees
- ✓Competitive starting price from $133
Cons
- ✗Semaglutide only — no tirzepatide or liraglutide
- ✗No visible LegitScript or PCAB accreditation
- ✗State availability not disclosed
- ✗Broader platform (hormones, sexual wellness, hair health)
Spry
Pros
- ✓Three named co-founders explicitly disclosed (Gabriel Mullins, Sara Yoder, Tyler Bowman) — better-than-average transparency vs anonymous DTC competitors
- ✓Pricing tier disclosed on homepage ($199 semaglutide / $299 tirzepatide / $249-$299 peptides) — no full sign-up wall
- ✓Broader product range (2 GLP-1s + 3 anti-aging peptides) appeals to longevity-buyer segment
- ✓No contracts or commitment requirements per FAQ
- ✓LegitScript Certified with public verification link
- ✓Same-day-24hr provider review intake speed
Cons
- ✗**YMYL CONCERN**: Site displays an 'FDA Approved' badge while selling compounded semaglutide and tirzepatide — compounded preparations are NOT FDA-approved finished drug products. This framing is potentially misleading vs the WLR transparency standard. The verbatim FDA compounded-medication disclaimer used by transparent competitors (e.g., 'compounded medications are not FDA-approved as a finished drug product') is absent from the homepage.
- ✗LegitScript ID NUMBER not publicly displayed on the homepage (only the verification link)
- ✗Intake reviewed by NURSE PRACTITIONER (per FAQ verbatim) — not MD review like Rewinding RX's positioning
- ✗States-served list NOT disclosed publicly
- ✗Pharmacy partner NOT named
- ✗503A vs 503B compounding designation NOT specified
- ✗Corporate legal entity (LLC/Inc/PC) NOT disclosed
- ✗Site is fully JavaScript-rendered SPA — pricing + nav captured only via Chrome MCP, not WebFetch
- ✗Co-founder credentials (medical or otherwise) not disclosed in the team section
- ✗BPC-157 peptide is an unregulated longevity supplement with limited human efficacy data — its inclusion alongside FDA-recognized weight-loss compounded GLP-1s reflects the broader functional-medicine positioning vs evidence-grade weight-loss specialist
Our Verdict
Actin edges out Spry with a higher overall score of 7.0/10 and is particularly strong for affordable compounded semaglutide with B12 enhancement. Spry remains a solid alternative, especially if you're looking for Buyers seeking a multi-product wellness/longevity platform that combines compounded GLP-1s with anti-aging peptides under one membership, who are comfortable with nurse-practitioner intake review (vs MD) and willing to overlook the 'FDA Approved' badge framing on a compounded-medication platform..
Glossary references
Key terms in this article, linked to their canonical definitions.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.